Arcturus Therapeutics
ARCTARCT · Stock Price
Historical price data
Overview
Arcturus Therapeutics is a fully integrated, commercial-stage biotech focused on developing mRNA medicines for infectious diseases and rare genetic disorders. Its key achievement is the global approval of KOSTAIVE®, the world's first authorized self-amplifying mRNA COVID-19 vaccine, validating its proprietary technology platforms. The company's strategy is to leverage its LUNAR® delivery and STARR™ saRNA platforms to build a diversified pipeline, advance wholly-owned rare disease programs, and expand through strategic partnerships for vaccines and therapeutics.
Technology Platform
Proprietary LUNAR® lipid-mediated delivery system for targeted nucleic acid delivery and STARR™ self-amplifying mRNA (saRNA) technology for enhanced and durable protein expression from lower doses.
Pipeline
15| Drug | Indication | Stage | Watch |
|---|---|---|---|
| ARCT-2303 + Influenza vaccine + Influenza vaccine, adjuvante... | COVID-19 | Phase 3 | |
| ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine + Astra Zene... | COVID-19 Vaccines | Phase 2/3 | |
| ARCT-032 | Cystic Fibrosis | Phase 2 | |
| ARCT-810 | OTC Deficiency | Phase 2 | |
| ARCT-021 single dose priming + ARCT-021 two lower dose primi... | Covid19 | Phase 2 |